- Global Pharma News & Resources

Basal-cell Carcinoma Therapeutics: Worldwide Market Analysis & Outlook 2018-2022 - Leading Players are Bausch Health, Biofrontera, F. Hoffmann-La Roche, Mylan, and Sun Pharmaceutical -

The "Global Basal cell Carcinoma Therapeutics Market 2018-2022" report has been added to's offering.

The basal cell carcinoma therapeutics market will register a CAGR of around 6% by 2022.

The advancements in the field of oncology research is expected to help the market grow during the forecast period. The key players in the market are constantly developing medicines for various cancer indications.

The market is expected to be driven by the heavy investments incurred to develop a strong R&D department for basal cell carcinoma treatment. Cancer is considered one of the most common causes of death across the globe, and the prevalence of cancer has witnessed a rapid surge in the past few years.

One of the major challenges faced by the global basal cell carcinoma therapeutics market is the availability of non-therapeutic treatment options such as surgeries.

With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities. Some of the established pharmaceutical companies and various government organizations are investing profoundly in the R&D of novel therapies, which is currently dominated by biologic molecules due to their high effectiveness.

Key Players

  • Bausch Health
  • Biofrontera
  • F. Hoffmann-La Roche
  • Mylan
  • Sun Pharmaceutical

Topics Covered

1. Executive Summary

2. Scope of the Report

3. Research Methodology

4. Disease Overview

5. Market Landscape

6. Market Sizing

7. Five Forces Analysis

8. Pipeline

9. Market Segmentation by RoA

10. Customer Landscape

11. Regional Landscape

12. Decision Framework

13. Drivers and Challenges

14. Market Trends

15. Vendor Landscape

16. Vendor Analysis

For more information about this report visit

View source version on

Editor Details

Last Updated: 06-Dec-2018